Opendata, web and dolomites

SHIGETECVAX SIGNED

Early clinical development of a live, attenuated combination vaccine against Shigella and ETEC diarrhoea

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SHIGETECVAX project word cloud

Explore the words cloud of the SHIGETECVAX project. It provides you a very rough idea of what is the project "SHIGETECVAX" about.

blocking    burden    shigellosis    etec    lps    caused    generations    mucosal    disease    multiple    too    pathogens    antibodies    radically    complementary    epidemiology    first    advantage    shigetec    almost    pathogen    huge    vaccines    expertise    attenuated    adults    infections    immunodominant    bangladesh    vaccine    detoxified    vaccination    sero    ing    recognition    antigens    pillars    antigen    gut    populations    doses    reactogenic    reduce    costly    oral    neutralizing    live    candidates    trial    protection    serotypes    shigella    entails    natural    attempts    toxin    designed    possibly    invasiveness    solution    shared    protecting    enteric    cell    safer    immune    although    molecular    failed    manufacture    disruption    efforts    immunity    advancing    lmics    safety    critical    additional    invasion    immunogenicity    endemic    rational    human    administration    diarrhoea    induce    clinical    surface    material    closely    virulence    elimination   

Project "SHIGETECVAX" data sheet

The following table provides information about the project.

Coordinator
EUROPEAN VACCINE INITIATIVE EWIV 

Organization address
address: VOSSSTRASSE 2 GEB 4040
city: HEIDELBERG
postcode: 69115
website: http://www.euvaccine.eu/

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 0 €
 EC max contribution 8˙603˙989 € (0%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2018-Two-Stage-RTD
 Funding Scheme RIA-LS
 Starting year 2019
 Duration (year-month-day) from 2019-09-01   to  2024-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EUROPEAN VACCINE INITIATIVE EWIV DE (HEIDELBERG) coordinator 359˙755.00
2    EVELIQURE BIOTECHNOLOGIES GMBH AT (WIEN) participant 5˙024˙401.00
3    INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH BANGLADESH BD (DHAKA) participant 1˙924˙713.00
4    GOETEBORGS UNIVERSITET SE (GOETEBORG) participant 749˙842.00
5    PATH US (SEATTLE) participant 545˙277.00

Map

 Project objective

Although vaccination is an effective way to reduce the huge disease burden associated with diarrhoea caused by enteric pathogens, many attempts to develop vaccines for shigellosis and ETEC infections have failed and a number of current approaches are too complex and costly to provide an adequate solution for LMICs. This Consortium is dedicated to advancing a radically new approach against Shigella and ETEC based not on the immunodominant, but highly variable Shigella LPS O-antigen, target of almost all past and current vaccine development efforts. There are four pillars on which the ShigETEC vaccine has been designed: (i) Elimination of the LPS O-antigen to allow recognition of multiple antigens on the cell surface that are shared among different serotypes of Shigella and are increasingly being recognized as important in protection from shigellosis. These antigens are also closely related to those of ETEC and may also help in protecting against that pathogen as well. (ii) Elimination of the invasiveness of Shigella by disruption of the invasion complex resulting in a much safer/less reactogenic oral vaccine that can take advantage of gut mucosal immunity, possibly allowing administration of high vaccine doses and therefore addresses the low immunogenicity seen with other live attenuated vaccine candidates. (iii) Addition of detoxified toxin antigens of ETEC that will induce neutralizing/blocking antibodies to these critical virulence factors. (iv) Rational molecular design of ShigETEC will allow future generations of vaccines to include additional antigens for other pathogens. The work programme entails manufacture of clinical trial material, first-in-human testing for safety and immunogenicity in non-endemic adults, a sero-epidemiology study to learn about natural immune response to the vaccine, and importantly testing the vaccine in endemic populations. The Consortium comprises partners from EU and Bangladesh that bring along highly complementary expertise.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SHIGETECVAX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SHIGETECVAX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

DIAdIC (2019)

Evaluation of Dyadic Psychoeducational Interventions for People with Advanced Cancer and their Informal Caregivers (DIAdIC): An international randomized controlled trial

Read More